Cite
Mpakou V, Spathis A, Bouhla A, et al. Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1. Exp Ther Med. 2021;21(3):195doi: 10.3892/etm.2021.9628.
Mpakou, V., Spathis, A., Bouhla, A., Mpazani, E., Papageorgiou, S., Gkontopoulos, K., Glezou, E., Thomopoulos, T., Foukas, P., & Pappa, V. (2021). Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1. Experimental and therapeutic medicine, 21(3), 195. https://doi.org/10.3892/etm.2021.9628
Mpakou, Vassiliki, et al. "Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1." Experimental and therapeutic medicine vol. 21,3 (2021): 195. doi: https://doi.org/10.3892/etm.2021.9628
Mpakou V, Spathis A, Bouhla A, Mpazani E, Papageorgiou S, Gkontopoulos K, Glezou E, Thomopoulos T, Foukas P, Pappa V. Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1. Exp Ther Med. 2021 Mar;21(3):195. doi: 10.3892/etm.2021.9628. Epub 2021 Jan 08. PMID: 33488804; PMCID: PMC7812574.
Copy
Download .nbib